Progress of Research on Therapeutic Drug Monitoring in Treatment of Novel Biological Agents for Inflammatory Bowel Disease / 胃肠病学
Chinese Journal of Gastroenterology
; (12): 680-685, 2022.
Article
em Zh
| WPRIM
| ID: wpr-1016070
Biblioteca responsável:
WPRO
ABSTRACT
Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disease, and its treatment includes traditional medicines and biological agents. Therapeutic drug monitoring is an important tool to optimize the treatment of biological agents. Therapeutic drug monitoring of tumor necrosis factor inhibitors has been used to guide the clinical decision ⁃ making. However, the value of therapeutic drug monitoring of novel biological agents (vedolizumab and ustekinumab) in IBD remains unclear. This article summarized the pharmacokinetics, drug concentration and treatment outcome, optimization of the novel biological agents in the treatment of IBD.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Gastroenterology
Ano de publicação:
2022
Tipo de documento:
Article